Multivariable Cox regression analysis of overall survival
| Discovery cohort (n=53) | Confirmation cohort (n=126) | Validation cohort (n=158) | ||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| MGR | ||||||
| ≤3.9 mm/month | 1 | 1 | 1 | |||
| >3.9 mm/month | 9.1 (3.2 to 25.4) | <0.0001 | 3.8 (2.1 to 6.7) | <0.0001 | 2.9 (1.6 to 5.3) | 0.00036 |
| Diameter of largest TL | ||||||
| ≤Median | 1 | 1 | 1 | |||
| >Median | 0.3 (0.1 to 0.9) | 0.022 | 1.3 (0.6 to 3.0) | 0.47 | 0.7 (0.3 to 1.5) | 0.34 |
| Sum of RECIST TLs | ||||||
| ≤Median | 1 | 1 | 1 | |||
| >Median | 3.1 (1.0 to 9.6) | 0.046 | 0.6 (0.3 to 1.3) | 0.16 | 1.3 (0.6 to 2.7) | 0.45 |
| Liver metastasis | ||||||
| No | 1 | 1 | 1 | |||
| Yes | 2.4 (0.9 to 6.5) | 0.081 | 2.0 (1.1 to 3.4) | 0.016 | 2.0 (1.2 to 3.3) | 0.0088 |
| CNS metastasis | ||||||
| No | 1 | 1 | 1 | |||
| Yes | 2.9 (1.1 to 8.2) | 0.039 | 2.2 (1.3 to 3.8) | 0.0058 | 1.3 (0.7 to 2.4) | 0.40 |
| LDH | ||||||
| ≤ULN | 1 | 1 | 1 | |||
| >ULN | 1.6 (0.7 to 3.8) | 0.28 | 1.7 (0.9 to 3.1) | 0.081 | 1.5 (0.9 to 2.5) | 0.16 |
| Line of treatment | ||||||
| First line | 1 | 1 | 1 | |||
| Second line | 0.8 (0.3 to 2.4) | 0.73 | 0.7 (0.4 to 1.3) | 0.28 | 2.0 (1.1 to 3.9) | 0.033 |
| ≥Third line | 0.9 (0.2 to 3.1) | 0.84 | 1.0 (0.5 to 1.9) | 0.96 | 2.3 (1.2 to 4.3) | 0.012 |
CNS, central nervous system; LDH, lactate dehydrogenase; MGR, metastatic growth rate; RECIST, response evaluation criteria in solid tumors version 1; ULN, upper limit of normal.